Abstract
To explore the clinical features and significance of "notch" in reactivation of retinopathy of prematurity (ROP) post-intravitreal ranibizumab (IVR) monotherapy. Ninety-six infants (173 eyes) with type 1 or aggressive ROP (A-ROP) post-IVR monotherapy were retrospectively analyzed; 51 eyes were notch (+) and 122 eyes were notch (-). General demographics and clinical outcomes were compared by notch status for type 1 and A-ROP. The notch primarily appeared in stage 2 ROP (84.4 and 78.9%) at the junction of zones I and II (68.8 and 63.2%) on the temporal side in type 1 ROP and A-ROP. Notch was present in the type 1 ROP group before first IVR but post-treatment in the A-ROP group. A significantly higher reactivation rate, longer follow-up duration, and postmenstrual age at last follow-up were seen in the notch (+) versus the notch (-) group. In the notch (+) ROP group, the mean gestational age (28.34±0.93 vs. 29.94±1.48 weeks) was significantly lower in reactivated versus regressed eyes. Notches appeared at different times but similar locations in type 1 ROP and A-ROP. The reactivation rate after IVR was increased in ROP with notches. Notch may be a useful biomarker for reactivation after IVR in ROP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
